Sono-Tek Corp. 10-Q Summary: Quarter Ended May 31, 2009
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended May 31, 2009. Sono-Tek Corporation designs and manufactures ultrasonic atomizing nozzles and coating systems for electronics, medical devices, and industrial applications. The company is classified as a smaller reporting company and a non-accelerated filer. As of June 29, 2009, there were 14,414,714 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2010 (Ended May 31, 2009) | Q1 2009 (Ended May 31, 2008) |
|---|---|---|
| Net Sales | $1,464,728 | $1,620,521 |
| Gross Profit | $657,381 | $788,864 |
| Gross Margin | 44.9% | 48.7% |
| Operating Loss | $(170,561) | $(139,271) |
| Net Loss | $(169,427) | $(130,458) |
| EPS (Basic & Diluted) | $(0.01) | $(0.01) |
| Cash from Operations | $119,376 | $(709,549) |
| Cash and Equivalents (End of Period) | $1,471,379 | $1,553,573 |
| Total Debt (Current + Long Term) | $286,521 | Not explicitly totaled in text |
| Working Capital | $2,704,268 | $2,897,852 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by approximately 10% ($156,000) compared to the prior year quarter. This was driven by lower sales of fluxer units, nozzles, and WideTrack units, partially offset by growth in programmable coating units and stent coating systems.
- Margin Compression: Gross profit margin declined from 49% to 45% due to lower sales volume and a product mix shift toward items with lower margins.
- Expense Reduction: Operating expenses decreased by roughly $100,000. General and administrative costs dropped significantly ($61,000) due to voluntary reductions in officer salaries and lower stock-based compensation. R&D costs also fell by $35,000.
- Cash Flow Improvement: Operating cash flow turned positive ($119,376) compared to a significant outflow ($709,549) in the prior year. This improvement was driven by a $210,000 reduction in accounts receivable and a $61,000 reduction in inventory.
- Equity Reduction: Stockholders' equity decreased by $156,000, primarily due to the net loss for the period.
Outlook, Risks, and Contingencies
- Market Strategy: Management continues to diversify away from the cyclical US electronics market, which has declined due to offshore production trends. Growth is being pursued in international markets (now ~59% of revenue), medical devices (stent coating), and clean energy (solar/fuel cells).
- Liquidity: The company maintains a $500,000 revolving line of credit with $250,000 currently utilized. The unused portion provides a buffer, though the line requires an annual 30-day paydown.
- Contingency: The company is recovering funds from a former employee who misappropriated approximately $250,000. While ~75% has been recovered, the remaining balance is considered questionable, and a promissory note has been fully reserved.
- Risks: Forward-looking statements highlight risks related to general economic conditions, the ability to enforce patents, and the success of new product development in emerging markets.
Investor Verification Checklist
- Revenue Sustainability: Verify if the shift to international and medical markets can sustainably offset the decline in US electronics sales.
- Debt Covenants: Confirm the company's ability to meet the annual 30-day paydown requirement on its $500,000 line of credit to avoid conversion to a term note.
- Inventory Valuation: Review the $315,198 allowance for inventory obsolescence to ensure it remains adequate given the product mix changes.
- Recovery of Misappropriated Funds: Monitor the status of the remaining 25% of funds misappropriated by the former employee.
- Profitability Path: Assess whether the reduction in operating expenses is a one-time benefit or a sustainable structural change to achieve profitability.